BFEC
RPRX icon

Benjamin F. Edwards & Company’s Royalty Pharma RPRX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-43
Closed -$2K – 1894
2022
Q2 		$2K Buy
+43
New +$1.76K ﹤0.01% 1709

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Benjamin F. Edwards & Company's RPRX Position: Q3 2022 in Review

Benjamin F. Edwards & Company sold out of Royalty Pharma (RPRX) in Q3 2022, closing a stake of 43 shares — an estimated $2K sold.

Benjamin F. Edwards & Company first reported a position in RPRX in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

  • Benjamin F. Edwards & Company reported no remaining Royalty Pharma position as of Q3 2022 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 43 Royalty Pharma shares in Q3 2022, an estimated $2K.
  • Benjamin F. Edwards & Company first reported a position in Royalty Pharma in Q2 2022 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Royalty Pharma position peaked at $2K in Q2 2022.
  • 319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2022, filed 28 Oct 2022.